AL
ALINT.PA Integragen
- Market cap
- EUR 497K
- P/E
- -
- P/B
- 0.58x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- 0.3/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is ALINT.PA undervalued?
Graham numberThe Graham number of Integragen cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Integragen fundamental analysis
1 of 11 checks passedROE 0/2
Negative ROE (-0.16%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.
ROA 0/2
The stock's ROA (-0.04%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.
PBV 0/2
The stock's elevated P/BV ratio (3.04x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.
DER 1/2
The stock maintains a fair debt to equity ratio (77%), indicating a reasonable balance between the money it owes and the ownership it possesses.
Revenue Growth 0/2
Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.
Net Profit Growth 0/2
Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.
Assets Growth 0/2
Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.
Graham Number 0/1
The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.
Dividend Growth 0/2
The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.
Dividend 0/2
The company's lack of dividends in the past three years may concern investors seeking regular income.
Buffet Intrinsic Value 0/1
Warren Buffett's formula suggests that the company's stock is overpriced (-1.900), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Integragen stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Integragen
IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. The company's genomic pharma services DNA sequencing for oncology and rare disease research; and NGS testing for cancer research. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing …
Full company profileIntegragen financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Integragen annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.27M | 6.51M | 6.95M | 8.28M | 8.98M | 11.3M | 13.2M | 12.5M | 8.70M | 5.02M | 7.92M |
| Gross Profit | 1.44M | 1.26M | 2.40M | 5.72M | -89.5K | 43.7K | -6.36K | -6.98K | 1.79M | -2.37M | -6.32M |
| Operating Income | -1.78M | -1.93M | -1.18M | -363K | -254K | -29.5K | -139K | -184K | -807K | -2.82M | -6.32M |
| EBITDA | -1.67M | -1.81M | -1.20M | -179K | -236K | 96.5K | 70.0K | -52.5K | -296K | -2.78M | -6.26M |
| Net Income | -1.65M | -862K | -1.14M | -285K | -375K | 15.4K | -3.51K | -171K | -256K | -2.66M | -4.22M |
| EPS | -0.33 | -0.13 | -0.18 | -0.04 | -0.06 | 0.00 | 0.00 | -0.03 | -0.04 | -0.40 | -0.63 |
| Balance Sheet | |||||||||||
| Total Assets | 7.59M | 8.65M | 8.58M | 6.75M | 8.82M | 9.60M | 9.02M | 8.00M | 5.52M | 2.81M | 1.46M |
| Total Liabilities | 6.31M | 4.72M | 5.79M | 4.24M | 6.65M | 7.42M | 6.82M | 5.99M | 3.76M | 2.71M | 3.43M |
| Shareholders' Equity | 1.28M | 3.93M | 2.79M | 2.51M | 2.17M | 2.19M | 2.20M | 2.01M | 1.76M | -909K | -1.96M |
| Cash & Short-term Investments | 2.73M | 4.13M | 4.01M | 2.81M | 5.12M | 4.78M | 4.51M | 2.88M | 1.90M | 1.12M | 174K |
| Total Debt | 323.00 | 343.00 | 359K | 301K | 2.08M | 2.27M | 1.67M | 1.12M | 643K | 305K | 305K |
| Cash Flow | |||||||||||
| Operating Cash Flow | 106K | 123K | 136K | 256K | 453K | 412K | 403K | - | - | -1.58M | - |
| Capital Expenditure | 333K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.27K | - |
| Free Cash Flow | -227K | 123K | 136K | 256K | 453K | 412K | 403K | - | - | -1.58M | - |
| Ratios | |||||||||||
| ROE | -128.7% | -21.9% | -40.8% | -11.4% | -17.3% | 0.7% | -0.2% | -8.5% | -14.6% | - | - |
| ROA | -21.7% | -10.0% | -13.3% | -4.2% | -4.3% | 0.2% | 0.0% | -2.1% | -4.6% | -95.0% | -288.4% |
| Net Profit Margin | -26.3% | -13.2% | -16.4% | -3.4% | -4.2% | 0.1% | 0.0% | -1.4% | -2.9% | -53.1% | -53.2% |
| Debt to Equity | 0.00x | 0.00x | 0.13x | 0.12x | 0.96x | 1.04x | 0.76x | 0.56x | 0.37x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Integragen dividends
Integragen has not paid dividends in the last 10 fiscal years.
Who owns Integragen
- Insiders 65.90%
- Institutions 0.00%
- Public & others 34.11%
- Shares outstanding 6.61M
- Free float 2.36M
Integragen company profile
- Company name
- Integragen
- Ticker
- ALINT.PA
- ISIN
- FR0010908723
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 37
- Fiscal year end
- December
- Address
- Genopole Campus 1 BAt. 8, Évry, France, 91000
- Phone
- 33 1 60 91 09 00
- Website
- integragen.com
About Integragen
IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. The company's genomic pharma services DNA sequencing for oncology and rare disease research; and NGS testing for cancer research. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing into a molecular report for translational and clinical research use; Galileo, a cloud-based app for dynamic exporation of RNA-Seq expression data; and GeCo, a genomic consulting service that offers researchers with access to biostatistics and bioanalytics experts. IntegraGen SA was incorporated in 2000 and is headquartered in Évry, France. IntegraGen SA operates as a subsidiary of OncoDNA SA.
Integragen management
5- Ms. Berengere GeninGeneral Manager
- Ms. Anne PhilippiCo-Founder and Director of Bio-Statistics & Genetic Epidemiology
- Ms. Beatrice CosperecLegal Manager
- Ms. Celine CaperaSales Manager
- Manuelle PuisantDirector of Human Resources